THE UNIVERSITY OF MISSISSIPPI - THE COMMON PERCEPTION THAT A LABEL OF 'NATURAL' ENSURES SAFETY, THE UNPLEASANT EPISODES AND SIDE EFFECTS ASSOCIATED WITH PHARMACEUTICAL (SYNTHETIC) DRUGS, ALONG WITH THE LONG HISTORY OF USAGE OF BOTANICALS AS MEDICINES, HAVE RESULTED IN T
Key Details
Description
THE COMMON PERCEPTION THAT A LABEL OF 'NATURAL' ENSURES SAFETY, THE UNPLEASANT EPISODES AND SIDE EFFECTS ASSOCIATED WITH PHARMACEUTICAL (SYNTHETIC) DRUGS, ALONG WITH THE LONG HISTORY OF USAGE OF BOTANICALS AS MEDICINES, HAVE RESULTED IN T
Context & Analysis
On Dec 19, 2025, Department of Health and Human Services obligated $1,599,513 to THE UNIVERSITY OF MISSISSIPPI for the common perception that a label of 'natural' ensures safety, the unpleasant episodes and side effects associated with pharmaceutical (synthetic) drugs, along with the long history of usage of botan…. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a cost no fee contract. Competition extent: full and open competition with 1 offer received. The procurement used a NO SET ASIDE USED. set-aside. Performance is located in SILVER SPRING, MD. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.